ALUR

Allurion Technologies, Inc.
CAPPED RATING

Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon) and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. The company is headquartered in Natick, Massachusetts.

Allurion Technologies, Inc. (ALUR) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (C+); its weakest is Growth (D-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.2 / 5.0
C
Value
C+
Factor Score 2.7 / 5.0
Growth
D-
Factor Score 1.1 / 5.0
Profitability
C+
Factor Score 2.8 / 5.0
Momentum
C
Factor Score 2.4 / 5.0
Revisions
C-
Factor Score 1.9 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 0.0
EV / EBITDA -2.1
Rev Growth YoY -47.2%
Gross Margin 52.7%
Price Return 3M -62.3%
Price Return 12M -86.8%
Catalyst Signal 0.00
Market Cap N/A
TTM Revenue N/A
Price / Sales 0.3
ROE 0.0%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-08-05 C+ (2.7) D- (1.1) C+ (2.8) C (2.4) C- (1.9) C (2.2)
2026-08-04 C+ (2.7) D- (1.1) C+ (2.8) C (2.4) C- (1.9) C (2.2)
2026-08-03 C+ (2.7) C- (2.1) B- (3.0) C (2.4) C- (2.0) C (2.4)
2026-08-02 C+ (2.7) C- (2.1) B- (2.9) C (2.4) C- (1.9) C (2.4)